Diamyd Medical
14.32
SEK
-2.59 %
DMYD B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
-2.59%
+9.15%
-4.53%
+20.13%
+117.96%
+106.04%
+27.43%
+96.61%
+374.69%
www.diamyd.com
Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.
Revenue
130K
EBIT %
-112,746.15 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
DMYD B
Daily low / high price
14.28 / 15.08
SEK
Market cap
1.49B SEK
Turnover
2.27M SEK
Volume
154K
Latest videos
Financial calendar
General meeting
05.12.2024
Interim report
29.01.2025
Interim report
09.04.2025
Interim report
25.06.2025
Annual report
08.10.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Avanza Pension | 12.2 % | 9.7 % |
| Bertil Lindkvist | 8.7 % | 6.9 % |
| Nordnet Pension | 5.6 % | 4.4 % |
| Anders Essen-Möller | 3.9 % | 9.0 % |
| Maria-Teresa Essen-Möller | 1.4 % | 4.0 % |
| Konstruktions o Försäljningsaktiebolag | 0.9 % | 0.7 % |
| Essen-Möller, Martin | 0.8 % | 3.5 % |
| Essen-Möller, Jon | 0.7 % | 3.7 % |
| Hillborg, Erika | 0.6 % | 3.7 % |
| Essenshaw, My | 0.5 % | 3.2 % |
ShowingAll content types
Diamyd Medical AB: Article published by ASSET, coordinated by Diamyd Medical, advocates for national screening programs in Sweden for early detection of Type 1 Diabetes
Diamyd Medical AB: Diamyd Medical hits a recruitment milestone in DIAGNODE-3 Phase 3 trial
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools